Veru Inc. (VERU)
| Market Cap | 36.76M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -19.11M |
| Shares Out | 16.05M |
| EPS (ttm) | -1.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 26,156 |
| Open | 2.310 |
| Previous Close | 2.340 |
| Day's Range | 2.290 - 2.380 |
| 52-Week Range | 2.060 - 7.400 |
| Beta | -1.34 |
| Analysts | Strong Buy |
| Price Target | 22.50 (+882.53%) |
| Earnings Date | May 12, 2026 |
About VERU
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly pat... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for VERU stock is "Strong Buy." The 12-month stock price target is $22.5, which is an increase of 882.53% from the latest price.
News
Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
-- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients...
Veru Inc. Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Enobosarm, combined with GLP-1, aims to address muscle loss and functional decline in older obese patients, with Phase 2b studies showing promising results in lean mass preservation and fat loss. The upcoming Plateau study targets regulatory approval through multiple endpoints, with top-line data expected in Q4 2027.
Veru Inc. Earnings Call Transcript: Q1 2026
Net loss narrowed to $5.3M as R&D and admin costs declined, with $33M in cash supporting operations through the next clinical milestone. Positive phase II-B results and FDA feedback advance enobosarm's development for obesity, targeting selective fat loss and muscle preservation.
Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th
MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a...
Veru Inc. Earnings Call Transcript: Q4 2025
Positive Phase 2b results for enobosarm showed preserved lean mass and enhanced fat loss in obese patients on GLP-1 therapy. Divestiture of the FC2 business and a public offering strengthened the financial position, supporting the upcoming PLATEAU trial targeting older, high-BMI patients.
Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress
MIAMI, FL, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a...
Veru to Report Fiscal Year 2025 Financial Results on December 17th
MIAMI, FL, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a...
Veru to Present Two Abstracts at ObesityWeek 2025
MIAMI, FL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a...
Veru Announces Proposed Public Offering
MIAMI, FL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a...
Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity
MIAMI, FL, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic ...
Veru Inc. Earnings Call Transcript: Q3 2025
Phase II-B data showed enobosarm + semaglutide preserved lean mass and enhanced fat loss in older adults with obesity, with a strong safety profile. Financials reflect a narrowed focus on drug development, reduced losses, and the need for additional capital to fund Phase III trials.
Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress
--Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal side...
Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study
MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and i...
Veru Announces Reverse Stock Split
MIAMI, FL, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a...
Veru to Participate in the 2025 BTIG Virtual Biotech Conference
MIAMI, FL, July 22, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a...
Veru to Participate in the Virtual BTIG Obesity Health Forum
MIAMI, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a...
Veru's Enobosarm Shows Muscle In Wegovy Combo Trial
Penny stock Veru Inc. VERU on Wednesday released topline safety results from the Phase 2b QUALITY study of enobosarm 3mg, enobosarm 6mg, or placebo to enhance fat loss and prevent muscle loss in patie...
Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone
--Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial...
JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s (NASDAQ:VERU) Enobosarm Taking GLP-1 Weight Loss to Next Level
Moderated discussion with preeminent obesity expert Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D.
Veru Participates in a Virtual Investor KOL Connect Segment
-- Moderated discussion with preeminent obesity expert, Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder, of Veru -- MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE) ...
Veru Inc. Earnings Call Transcript: Q2 2025
Phase IIB results showed Enobosarm plus semaglutide preserves lean mass and enhances fat loss in older obese patients, with positive safety signals and key regulatory and clinical catalysts expected this quarter. Cash runway extends into Q4 2025, but additional funding will be needed for phase III.
Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress
--Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the secon...
Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8
MIAMI, May 01, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and in...
Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit
MIAMI, FL, April 16, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic ...
Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference
MIAMI, FL, March 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic ...